Montana Pioneers Experimental Treatment Hub with New Legislation Expanding Right to Try
核心洞察
Montana (搜索)'s new legislation creates a regulatory framework for clinics to offer experimental drugs that have completed only Phase I clinical trials, positioning the state as a potential medical tourism hub.
The bill, supported by longevity enthusiasts and libertarians, requires manufacturing within state borders and mandates enhanced informed consent protocols, while allocating 2% of profits to support treatment access for Montana (搜索) residents.
Bioethicists express concerns about patient safety, noting that Phase I trials primarily assess safety in small groups and don't determine efficacy, with 90% of drug candidates ultimately failing clinical trials.
Montana (搜索) is poised to become America's first hub for experimental medical treatments following the passage of Senate Bill 535, which awaits Governor Greg Gianforte's expected signature. The groundbreaking legislation establishes a regulatory framework allowing clinics to sell drugs that have completed only Phase I clinical trials—the initial safety studies that don't yet determine efficacy.
The bill, which passed the state legislature on April 29 with bipartisan support, builds upon Montana (搜索)'s existing Right to Try (搜索) laws. While those laws were originally designed for terminally ill patients, this expansion creates infrastructure for clinics to legally provide experimental treatments to any Montana resident.
A Longevity Movement Initiative
The legislation was largely drafted and lobbied for by advocates from the longevity and life extension community—a coalition of scientists, libertarians, and influencers seeking to accelerate access to potential anti-aging (搜索) treatments.
"I see no reason why it couldn't be adopted by most of the other states," said Todd White, who helped develop the bill, at a recent Washington, DC event hosted by the Alliance for Longevity Initiatives (搜索) (A4LI). White, who directs a research organization focused on aging (搜索), believes the Montana (搜索) model could proliferate nationwide.
Dylan Livingston, founder and CEO of A4LI, collaborated with State Senator Kenneth Bogner to develop the 2023 expansion of Montana (搜索)'s Right to Try (搜索) law. The new legislation addresses practical implementation challenges by establishing licensing requirements for clinics and protecting prescribing physicians from disciplinary action.
"Now somebody who actually wants to deliver drugs under the Right to Try (搜索) law will be able to do so," White explained.
Medical Tourism Potential
Supporters envision Montana (搜索) becoming a domestic alternative to international medical tourism, where Americans currently travel to access experimental treatments unavailable in the U.S.
"If you're going to go and get an experimental gene therapy (搜索), you might as well keep it in the country," Livingston argued. "One: let's keep the money in the country, and two: if I was a millionaire getting an experimental gene therapy, I'd rather be in Montana (搜索) than Honduras."
Rep. Ed Buttrey, R-Great Falls, who carried the bill in the House, emphasized the potential for accelerated access to innovative therapies. "By allowing treatments prior to the completion of phase two and phase three trials, which are all about the efficacy of the treatments, we can get access for Montanans to innovative therapies many years before the therapies are available through standard medical care," Buttrey said during floor debate.
According to Livingston, several clinics are already planning to establish operations in Montana (搜索). "We have half a dozen that are interested, and maybe two or three that are definitively going to set up shop out there," he said, though he declined to name specific providers.
Enhanced Safety Protocols
The legislation includes provisions intended to strengthen patient protections. Before receiving experimental treatments, patients must provide written informed consent that includes a list of approved alternative drugs and descriptions of worst potential outcomes—requirements that go beyond existing Right to Try (搜索) laws.
"In the Montana (搜索) law, we explicitly enhanced the requirements for informed consent," said Niklas Anzinger, a tech entrepreneur and longevity enthusiast who collaborated on the bill. "We have to treat this with a very large degree of responsibility."
The bill also requires that experimental treatment centers allocate 2% of their net annual profits "to support access to experimental treatments and healthcare for qualifying Montana (搜索) residents," in an attempt to address equity concerns.
Scientific and Ethical Concerns
The legislation has drawn significant criticism from bioethicists and legal scholars who worry about patient safety and the ethics of promoting unproven treatments.
"It's disturbing that they want to make drugs available after phase I testing," said Sharona Hoffman, professor of law and bioethics at Case Western Reserve University. "This could endanger patients."
Phase I clinical trials typically involve fewer than 50 healthy volunteers and are designed primarily to check that a drug isn't immediately harmful—not to determine efficacy or identify rare side effects. Approximately 90% of drug candidates fail during clinical trials, with 17% failing late-stage trials specifically due to safety concerns.
"Famously, the doctor's first obligation is to first do no harm," noted bioethicist Alison Bateman-House of New York University. "If [a drug] has not been through clinical trials, how do you have any standing on which to think it isn't going to do any harm?"
Rep. Kathy Love, R-Hamilton, expressed similar concerns during House debate. "FDA clinical trials have stepped phases," Love said. "There's also usually an institutional review board that plays a crucial role in overseeing clinical trials, reviews, and approves the study's protocol to ensure that it meets ethical standards and complies with regulations. This bill doesn't provide for that."
Manufacturing Constraints and Future Outlook
A significant limitation of the Montana (搜索) law is that it only permits the sale of drugs manufactured within state borders, as federal law requires FDA approval for drugs distributed in interstate commerce. However, supporters note that Montana already hosts pharmaceutical manufacturing facilities, including Pfizer operations.
The legislation represents a bold experiment in medical regulation that could potentially reshape how Americans access experimental treatments. Proponents frame it as a matter of medical freedom and autonomy, while critics worry it undermines crucial safety protections established after historical pharmaceutical disasters.
"There is no other place in the world with this sort of regulatory environment," Livingston said, highlighting Montana (搜索)'s potential to become a unique destination for those seeking early access to experimental therapies.
As the bill awaits the governor's signature, both supporters and critics are watching closely to see how this unprecedented regulatory approach will unfold in practice—and whether other states might follow Montana (搜索)'s lead.